<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30109" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Superficial Thrombophlebitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Czysz</surname>
            <given-names>Augusta</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Higbee</surname>
            <given-names>Sheetal L.</given-names>
          </name>
          <aff>Conemaugh Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Augusta Czysz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sheetal Higbee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30109.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Superficial thrombophlebitis, increasingly known as superficial venous thrombosis, is no longer considered benign. It is often associated with concomitant deep venous thrombosis or pulmonary embolism, potentially due to a more sinister underlying issue. As such, there is limited consensus on treatment, which makes further study of this topic necessary. This activity reviews the evaluation and management of superficial venous thrombosis and highlights the healthcare team's role in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of superficial thrombophlebitis.</p></list-item><list-item><p>Identify critical elements in evaluating patients with superficial thrombophlebitis that predispose patients to concomitant deep vein thrombosis and pulmonary embolism.</p></list-item><list-item><p>Evaluate&#x000a0;the management options available for superficial thrombophlebitis.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies to improve coordination of care to advance the diagnosis of superficial thrombophlebitis, concomitant deep venous thrombosis, pulmonary embolism, and more sinister underlying causes and thereby improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30109&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30109">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30109.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Superficial thrombophlebitis is an inflammatory disorder of superficial veins with coexistent venous thrombosis.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r2">[2]</xref>&#x000a0;It usually affects lower limbs, particularly the great saphenous vein (60% to 80%) or the small/short saphenous vein (10% to 20%). However, it can occur at other sites (10% to 20%) and may occur bilaterally (5% to 10%).<xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref>&#x000a0;Traditionally, this relatively common process was considered benign and self-limited. More recently, superficial thrombophlebitis, also called superficial venous thrombosis (SVT), has&#x000a0;been associated with other venous thromboembolic disorders, primarily deep venous thrombosis (DVT) and pulmonary embolism (PE). Therefore, it involves more than a purely clinical diagnosis with supportive treatment.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref>&#x000a0;Affected patients have an increased risk for recurrence of venous thromboembolic events.<xref ref-type="bibr" rid="article-30109.r4">[4]</xref> Herein, the terms of superficial thrombophlebitis and&#x000a0;SVT&#x000a0;are&#x000a0;used interchangeably.</p>
      </sec>
      <sec id="article-30109.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>A hypercoagulable state, prolonged immobilization, or vessel wall trauma may increase the risk of SVT. Superficial thrombophlebitis accounts for 5.4% of the adjusted population attributable risk for initial DVT or PE. SVT has been the presenting symptom in certain inheritable thrombophilias. According to several studies, it occurs in 11% to 15% of patients with protein C or S deficiency and approximately 40% with factor V Leiden mutation.<xref ref-type="bibr" rid="article-30109.r5">[5]</xref>&#x000a0;However, another study showed that these results were not statistically significant.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;In pregnancy, the risk of SVT is akin to that of DVT, most commonly in the postpartum period. Advanced age, exogenous estrogens, autoimmune or infectious diseases, obesity, recent trauma or surgery, active malignancy, history of venous thromboembolic disease, and respiratory or cardiac failure also increase the risk of SVT.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Prior occurrences increase the risk of subsequent ones. As noted in 75% to 88% of cases, varicose veins are considered the most important clinically identifiable predisposing factor for SVT.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref></p>
      </sec>
      <sec id="article-30109.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The true incidence of superficial thrombophlebitis is unclear. In France,&#x000a0;1 community-based study noted the incidence of SVT to be 0.64%, while a different community-based study found the incidence to be half that of DVT and similar to PE.<xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Other studies suggest its prevalence in the general population is&#x000a0;2 to&#x000a0;6 times higher than the incidence of DVT and PE.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;SVT is commonly seen in the outpatient population, usually, women, who made up 50% to 70% of the affected patients in&#x000a0;1 study; 60 years mean age; a body mass index that exceeds 25 kg/m2; and those with varicose veins.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;For people who have a history of SVT, the lifetime risk of DVT or PE increases&#x000a0;4 to&#x000a0;6 times. While the 3-month mortality is about 5% in patients with DVT or PE, it is less than 1% for those with SVT. One suggested reason for the lower mortality in patients with SVT is the younger age of the patients with fewer associated comorbidities.<xref ref-type="bibr" rid="article-30109.r3">[3]</xref>&#x000a0;The migration of the thrombus towards the deep veins at the saphenofemoral junction, the saphenopopliteal junction, or from a perforating vein during a hypercoagulability state may cause the association between SVT and DVT or PE.<xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30109.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Superficial thrombophlebitis starts with microscopic thrombosis. When venous turbulence or stasis, vessel wall injuries, abnormal coagulability, or vessel wall injuries, microthrombi could propagate and subsequently form macroscopic thrombi. Vascular endothelial injury reliably results in thrombus formation by triggering&#x000a0;an inflammatory response that results in immediate platelet adhesion. Platelet aggregation is mediated by thrombin and&#x000a0;thromboxane A2.</p>
      </sec>
      <sec id="article-30109.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with superficial thrombophlebitis typically present with a reddened, warm, inflamed, tender area overlying the track of a superficial vein. There is often a palpable cord. Some surrounding edema or associated pruritis may occur. Significant swelling of the limb is more commonly associated with DVT and should only be attributed to SVT after DVT has been excluded.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r7">[7]</xref>&#x000a0;Patients may have a history of antecedent trauma, which can include&#x000a0;intravenous cannulation or infusion of irritants, such as&#x000a0;recent&#x000a0;sclerotherapy for varicose veins.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r8">[8]</xref>&#x000a0;A careful history is critical to identify risk factors for venous thromboembolism. Initial presentation in patients older than 40 without other risk factors should prompt consideration of underlying malignancy.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Patients with migratory thrombophlebitis, a well-documented paraneoplastic phenomenon, should also be further evaluated for underlying malignancy.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r9">[9]</xref>&#x000a0;Migratory thrombophlebitis is usually associated with pancreatic or other visceral malignancies and is often called Trousseau syndrome. It&#x000a0;can be&#x000a0;the presenting complaint in 5% to 15% of pancreatic cancer, particularly of the body and tail.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r9">[9]</xref><xref ref-type="bibr" rid="article-30109.r10">[10]</xref></p>
      </sec>
      <sec id="article-30109.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Traditionally, superficial thrombophlebitis was a clinical diagnosis. However, with the increased realization of association with concomitant DVT or PE, compressive ultrasonography is recommended.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Physical examination does not adequately identify the extent of the disease; it has been shown to underestimate it in up to 77% of instances. Compressive ultrasonography can identify concomitant DVT, evaluate the extent of the thrombus, and confirm the diagnosis.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;The Prospective Observational Superficial Thrombophlebitis (POST) study reviewed venous duplex screening of the affected lower limb and showed that 23.5% of patients had concurrent DVT. More than half of these DVTs were not contiguous with the SVT; 17% were noted to affect the contralateral lower extremity, while only 1% had an isolated DVT in the contralateral limb. These findings support the regular use of ultrasound to evaluate SVT. The POST study also sought to establish the ultrasonic findings that increased the likelihood of associated DVT. It found that the risk substantially increased if a perforating vein was involved, with an odds ratio of 8.1, or if an SVT was present less than 3 cm from the saphenofemoral junction, which had an odds ratio of 3.3.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;D-dimer testing is of limited utility in detecting SVT. It is variably elevated in SVT and cannot be used to distinguish isolated SVT from DVT.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref></p>
        <p>Experts debate whether patients who present with extensive superficial thrombophlebitis without an apparent inciting reason should have an evaluation for thrombophilia, given that hypercoagulability is associated with SVT. However, to date, no conclusive studies have identified causation between hypercoagulability and SVT.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref>&#x000a0;As previously mentioned, migratory thrombophlebitis warrants evaluation for visceral neoplasm.&#x000a0;Patients older than 40 years with their first episode of thrombophlebitis should also be evaluated for underlying neoplasm.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r9">[9]</xref> Superficial thrombophlebitis of the superficial breast veins is referred to as Mondor disease. A case series from 1992 noted a 12.7% risk of associated breast cancer, but it was a limited study, so it is argued that the incidence could have been overrepresented. Therefore, mammography could be considered in patients with this presentation.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref></p>
        <p>To help establish the pretest probability for the presence of DVT in patients with SVT, the Internal Carotid Artery Occlusion (ICARO) Study Group has outlined the following&#x000a0;5 variables:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Active malignancy (1.5 points)</p>
          </list-item>
          <list-item>
            <p>Limb edema (1.5 points)</p>
          </list-item>
          <list-item>
            <p>Age of fifty years or more (1 point)</p>
          </list-item>
          <list-item>
            <p>A ropelike sign (-1 point)</p>
          </list-item>
          <list-item>
            <p>Unprovoked SVT (-1 point)<xref ref-type="bibr" rid="article-30109.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>The ICARO Study Group suggested this scoring system to help when assessing such patients for coexisting DVT:</p>
        <list list-type="bullet">
          <list-item>
            <p>Low probability (less than zero points): 1.1% likelihood</p>
          </list-item>
          <list-item>
            <p>Intermediate probability (score of 0 to 1): 12.0% likelihood</p>
          </list-item>
          <list-item>
            <p>High probability (scored 1.5 or more points): 32.3% likelihood<xref ref-type="bibr" rid="article-30109.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>However, a recent study using this scoring system does not support its validity.<xref ref-type="bibr" rid="article-30109.r12">[12]</xref></p>
      </sec>
      <sec id="article-30109.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Despite the number of studies performed, there is still debate on the appropriate treatment for superficial thrombophlebitis. Multiple strategies have been proposed to control symptoms and decrease the extension of thrombosis and risk for PE in low-risk superficial thrombophlebitis.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref>&#x000a0;Low-risk thromboses are those not associated with the presence of or predisposition to other thromboembolic diseases. In these cases, the consensus is that nonsteroidal anti-inflammatory agents, heat, and anticoagulants are all reasonable.<xref ref-type="bibr" rid="article-30109.r7">[7]</xref>&#x000a0;Those who are at higher risk include patients with an SVT in the lower extremity that is at least 5 cm in length; SVT proximal to the knee, especially within 10 cm of the saphenofemoral junction; the presence of severe symptoms; greater saphenous vein involvement; previous SVT/venous thromboembolic disease; active malignancy; or recent surgery.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Based on the Cochrane review published in 2018, these patients should receive fondaparinux 2.5 mg/day subcutaneously for 45 days.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref></p>
        <p>This Cochrane review also evaluated topical and surgical treatments. Still, it noted that the data regarding these treatments and their effects on venous thromboembolic disease is too limited, so further studies are recommended at this time.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref>&#x000a0;Rivaroxaban 10 mg daily for 45 days was found to be non-inferior to fondaparinux in preventing venous thromboembolic complications, with a comparable safety profile in the SURPRISE trial. However, the Cochrane review recommended further research on its use and the other direct oral factor-X or thrombin inhibitors.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r13">[13]</xref>&#x000a0;Additionally, further study is recommended on the use of nonsteroidal anti-inflammatory agents and low molecular weight heparins.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref>&#x000a0;Multiple agents have been evaluated for treatment in patients who develop superficial thrombophlebitis from an infusion. Per the 2015 Cochrane review of this topic, there is no consensus recommendation on the safety, dose required, or therapy duration for topical treatments, nonsteroidal anti-inflammatory agents, or systemic anticoagulation.<xref ref-type="bibr" rid="article-30109.r8">[8]</xref>&#x000a0;Practices in the United Kingdom suggest using compression stockings with or without additional therapies. Still, there is no current recommendation for or against their use in the United States of America.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Antibiotics are useful only with clear infection.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref></p>
        <p>For Trousseau syndrome, the main priority is to eliminate the underlying malignancy. However, as this is commonly a challenge, heparin is the recommended treatment, given that multiple pathways contribute to developing the thrombus. Low molecular weight heparins have been used, but some have been less effective than heparin; therefore, further studies are recommended. Fondaparinux has also been evaluated but found to be less efficacious than heparin, and the utility of this agent also requires further study.<xref ref-type="bibr" rid="article-30109.r9">[9]</xref>&#x000a0;A case report on the topic recommended the initial treatment with heparin followed by oral anticoagulants but did not specify a particular agent or dosing schedule.<xref ref-type="bibr" rid="article-30109.r10">[10]</xref>&#x000a0;Mondor disease, discussed separately, is usually self-limited and benign and resolve in&#x000a0;4 to 8&#x000a0;weeks. However, if it is due to vasculitis, malignancy, or a hypercoagulable state, treatment is aimed at the underlying cause.<xref ref-type="bibr" rid="article-30109.r14">[14]</xref></p>
      </sec>
      <sec id="article-30109.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating a patient, it is essential to keep superficial thrombophlebitis on the differential. Other considerations include cellulitis, venous thromboembolic diseases, hematoma, lymphangitis, lymphedema, vasculitis, tendonitis or sports-related injuries, and venous insufficiency.<xref ref-type="bibr" rid="article-30109.r15">[15]</xref><xref ref-type="bibr" rid="article-30109.r16">[16]</xref><xref ref-type="bibr" rid="article-30109.r17">[17]</xref><xref ref-type="bibr" rid="article-30109.r18">[18]</xref><xref ref-type="bibr" rid="article-30109.r19">[19]</xref></p>
      </sec>
      <sec id="article-30109.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for Superficial thrombophlebitis is related to the underlying cause. Low-risk SVT is generally favorable, but there is a definite risk for recurrent disease. In those with higher-risk SVT, the overall prognosis is also positive with appropriate treatment. For those with SVT due to underlying malignancy, the prognosis is related to the causative process.</p>
      </sec>
      <sec id="article-30109.s11" sec-type="Complications">
        <title>Complications</title>
        <p>DVT and PE are significant complications of superficial thrombophlebitis. Multiple studies have found concomitant DVT with SVT in 6 to 36% of patients. These same studies clinically suspected concomitant PE in 2 to 13%, and regular performance of lung scans revealed the rate of asymptomatic PE approached 33%.<xref ref-type="bibr" rid="article-30109.r3">[3]</xref>&#x000a0;Other retrospective studies from both primary and secondary/tertiary centers reported concomitant DVT or symptomatic PE on the initial presentation to be 25 to 30%. About 5 to 7% of these patients had symptomatic PE.<xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref>&#x000a0;However, the incidence of coexisting PE increased to 17% with a more rigorous screening process for asymptomatic patients.<xref ref-type="bibr" rid="article-30109.r4">[4]</xref>&#x000a0;Patients with thrombus up to 3 cm from the saphenofemoral junction should be treated for DVT, given that 14 to 70% progress to DVT.<xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30109.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with a vascular surgeon may be sought in patients with Superficial thrombophlebitis who require anticoagulation but have contraindications to anticoagulation. It may also be an option for those with recurrent SVT in the setting of chronic venous insufficiency.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Hematology/oncology consultation may also be considered in patients with underlying thrombophilias or malignancies.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref></p>
      </sec>
      <sec id="article-30109.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated on the likelihood and significance of disease propagation and recurrence based on their risk factors. They should be advised of the need for further evaluation in the presence of migratory thrombophlebitis or if they are more than 40 years old at the time of their initial presentation and are without other risk factors for venous thromboembolic disease.</p>
      </sec>
      <sec id="article-30109.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Patients with superficial thrombophlebitis should have compressive ultrasonography of both the affected and contralateral limb to evaluate for concomitant venous thromboembolic disease. Anticoagulation with fondaparinux 2.5 mg/day should be considered in patients with superficial thrombophlebitis in the lower extremity that is at least 5 cm in length; SVT proximal to the knee, especially within 10 cm of the saphenofemoral junction; the presence of severe symptoms; greater saphenous vein involvement; previous SVT/venous thromboembolic disease; active malignancy; or recent surgery. Experts do not routinely recommend investigation for thrombophilia and underlying malignancy. In patients with migratory thrombophlebitis, further investigations for visceral malignancy should ensue.</p>
      </sec>
      <sec id="article-30109.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Given the incidence of concomitant venous thromboembolic disease and the possibility of extension, it is paramount for healthcare team members to recognize that superficial thrombophlebitis is no longer considered a benign entity.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r3">[3]</xref><xref ref-type="bibr" rid="article-30109.r4">[4]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref> Thus, if non-providers observe such symptoms, the concern can be brought to providers' attention. Providers should have a low threshold for ultrasounds of both the affected and contralateral limbs to evaluate for concurrent venous thromboembolic disease.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref>&#x000a0;Then, providers should treat accordingly.<xref ref-type="bibr" rid="article-30109.r1">[1]</xref><xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref><xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r13">[13]</xref>&#x000a0;According to existing guidelines, The patients may also require further evaluation for thrombophilias.<xref ref-type="bibr" rid="article-30109.r2">[2]</xref><xref ref-type="bibr" rid="article-30109.r5">[5]</xref>&#x000a0;It is also important&#x000a0;for the interprofessional health care team, comprised of clinicians, nurses, mid-level practitioners, and pharmacists, to recognize that migratory thrombophlebitis requires a team evaluation as it can be a rare presentation of visceral malignancy and for the best outcomes, a coordinated team effort to treat the patient.<xref ref-type="bibr" rid="article-30109.r6">[6]</xref><xref ref-type="bibr" rid="article-30109.r9">[9]</xref></p>
      </sec>
      <sec id="article-30109.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30109&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30109">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/superficial-thrombophlebitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30109">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30109/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30109">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30109.s17">
        <title>References</title>
        <ref id="article-30109.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Nisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wichers</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment for superficial thrombophlebitis of the leg.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Feb</month>
            <day>25</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD004982</fpage>
            <pub-id pub-id-type="pmid">29478266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scriven</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Superficial thrombophlebitis (superficial venous thrombosis).</article-title>
            <source>BMJ</source>
            <year>2015</year>
            <month>Jun</month>
            <day>22</day>
            <volume>350</volume>
            <fpage>h2039</fpage>
            <pub-id pub-id-type="pmid">26099257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000e9;cousus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bertoletti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frapp&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat?</article-title>
            <source>J Thromb Haemost</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>13 Suppl 1</volume>
            <fpage>S230</fpage>
            <page-range>S230-7</page-range>
            <pub-id pub-id-type="pmid">26149029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Minno</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Ambrosino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ambrosini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tremoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Minno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis.</article-title>
            <source>J Thromb Haemost</source>
            <year>2016</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>964</fpage>
            <page-range>964-72</page-range>
            <pub-id pub-id-type="pmid">26845754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tait</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baglin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laffan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Makris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keeling</surname>
                <given-names>D</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines on the investigation and management of venous thrombosis at unusual sites.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-38</page-range>
            <pub-id pub-id-type="pmid">22881455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahdi</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Superficial vein thrombosis: a current approach to management.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>168</volume>
            <issue>5</issue>
            <fpage>639</fpage>
            <page-range>639-45</page-range>
            <pub-id pub-id-type="pmid">25521017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maddox</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Seupaul</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>What Is the Most Effective Treatment of Superficial Thrombophlebitis?</article-title>
            <source>Ann Emerg Med</source>
            <year>2016</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>671</fpage>
            <page-range>671-2</page-range>
            <pub-id pub-id-type="pmid">26707361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Nisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peinemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Porreca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rutjes</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Treatment for superficial infusion thrombophlebitis of the upper extremity.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Nov</month>
            <day>20</day>
            <volume>2015</volume>
            <issue>11</issue>
            <fpage>CD011015</fpage>
            <pub-id pub-id-type="pmid">26588711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trousseau's syndrome: multiple definitions and multiple mechanisms.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>1723</fpage>
            <page-range>1723-9</page-range>
            <pub-id pub-id-type="pmid">17496204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaconu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mateescu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x00103;l&#x00103;ceanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jianu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>St&#x00103;nic&#x00103;</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.</article-title>
            <source>J Med Life</source>
            <year>2010</year>
            <season>Jan-Mar</season>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-9</page-range>
            <pub-id pub-id-type="pmid">20302205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pomero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Minno</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Tamburini Premunian</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Malato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pasca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barillari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fenoglio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siragusa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Minno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study.</article-title>
            <source>Thromb Res</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>136</volume>
            <issue>5</issue>
            <fpage>938</fpage>
            <page-range>938-42</page-range>
            <pub-id pub-id-type="pmid">26421909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frapp&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brosse</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Seffert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D&#x000e9;cousus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bertoletti</surname>
                <given-names>L</given-names>
              </name>
              <collab>STEPH Study Group</collab>
            </person-group>
            <article-title>Ruling out deep vein thrombosis in patients with superficial vein thrombosis: external validation of the ICARO score.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-101</page-range>
            <pub-id pub-id-type="pmid">30317413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schellong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Superficial vein thrombosis treated for 45&#x000a0;days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-204</page-range>
            <pub-id pub-id-type="pmid">26973347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mondor's Disease: A Review of the Literature.</article-title>
            <source>Intern Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>15</day>
            <volume>57</volume>
            <issue>18</issue>
            <fpage>2607</fpage>
            <page-range>2607-2612</page-range>
            <pub-id pub-id-type="pmid">29780120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Useche</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>de Castro</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Galvis</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Mantilla</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ariza</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of US in the evaluation of patients with symptoms of deep venous thrombosis of the lower extremities.</article-title>
            <source>Radiographics</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>1785</fpage>
            <page-range>1785-97</page-range>
            <pub-id pub-id-type="pmid">18936036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Fillman</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Dohse</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Re-examination of features to distinguish polyarteritis nodosa from superficial thrombophlebitis.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-71</page-range>
            <pub-id pub-id-type="pmid">23392132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hoak</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of superficial thrombophlebitis from lymphangitis by doppler ultrasound.</article-title>
            <source>Surg Gynecol Obstet</source>
            <year>1976</year>
            <month>Jul</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-5</page-range>
            <pub-id pub-id-type="pmid">936045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taute</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Melnyk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Podhaisky</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Alternative sonographic diagnoses in patients with clinical suspicion of deep vein thrombosis].</article-title>
            <source>Med Klin (Munich)</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>105</volume>
            <issue>9</issue>
            <fpage>619</fpage>
            <page-range>619-26</page-range>
            <pub-id pub-id-type="pmid">20878299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30109.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Malinak</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Pseudocellulitis Need Not be Benign: Three Cases of Superficial Migratory Thrombophlebitis with "Negative" Venous Duplex Ultrasonography.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>49</fpage>
            <page-range>49-51</page-range>
            <pub-id pub-id-type="pmid">29399267</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
